Option Care Health (NASDAQ:OPCH) Receives “Outperform” Rating from Barrington Research

Barrington Research reiterated their outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a research note published on Wednesday morning, Benzinga reports. Barrington Research currently has a $38.00 target price on the stock. Barrington Research also issued estimates for Option Care Health’s Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group boosted their target price on Option Care Health from $36.00 to $38.00 and gave the stock a buy rating in a research report on Monday, March 4th.

Option Care Health Trading Down 2.2 %

OPCH opened at $29.93 on Wednesday. The firm has a 50 day simple moving average of $32.13 and a 200 day simple moving average of $31.52. Option Care Health has a fifty-two week low of $24.23 and a fifty-two week high of $35.74. The company has a market cap of $5.20 billion, a price-to-earnings ratio of 19.69, a price-to-earnings-growth ratio of 1.74 and a beta of 1.22. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.33.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The company had revenue of $1.15 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the previous year, the company posted $0.21 EPS. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Option Care Health will post 1.13 earnings per share for the current year.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. acquired 35,000 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were acquired at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the acquisition, the director now directly owns 269,528 shares of the company’s stock, valued at approximately $8,503,608.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of Option Care Health by 157.1% in the fourth quarter. Wellington Management Group LLP now owns 7,445,556 shares of the company’s stock valued at $250,841,000 after purchasing an additional 4,549,164 shares during the last quarter. Vanguard Group Inc. lifted its position in Option Care Health by 11.8% during the 3rd quarter. Vanguard Group Inc. now owns 19,319,352 shares of the company’s stock worth $624,981,000 after buying an additional 2,037,162 shares in the last quarter. Third Point LLC boosted its stake in shares of Option Care Health by 55.7% during the 3rd quarter. Third Point LLC now owns 5,450,659 shares of the company’s stock worth $176,329,000 after buying an additional 1,950,659 shares during the last quarter. Norges Bank bought a new position in shares of Option Care Health in the 4th quarter valued at about $64,343,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Option Care Health in the third quarter valued at about $36,239,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.